NCT01517490

Brief Summary

Retinal function is highly dependent on the glucose supply. Thus, functional adaptations occur in response to both acute and long-term changes in glycaemia. The purpose of this study is to examine functional and metabolic aspects of retinal adaptation to long-lasting changes in glycaemic control in patients with diabetes. The adaptational phenomena will be characterized by electroretinography, dark adaptation, measures of retinal perfusion and oximetry as well as diabetic retinopathy grading and (OCT).

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

January 23, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 25, 2012

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Last Updated

March 11, 2015

Status Verified

March 1, 2015

Enrollment Period

5.3 years

First QC Date

January 23, 2012

Last Update Submit

March 10, 2015

Conditions

Outcome Measures

Primary Outcomes (2)

  • Changes in dark adaptation kinetics and threshold values, amplitudes/implicit times, retinal vessel diameters, perfusion velocity and oximetry.

    Baseline, 1 week, 1 month, 4 months, 7 months, 12 months, 18 months, 24 months, 42 months

  • Changes in visual acuity, diabetic retinopathy grading and OCT

    Baseline, 1 week, 1 month, 4 months, 7 months, 12 months, 18 months, 24 months, 42 months

Study Arms (6)

Type 1 Insulin Pump

Patients with type 1 diabetes starting insulin pump treatment

Other: Insulin pump

Type 1 conventional therapy

Patients with type 1 diabetes continuing treatment with multiple daily insulin injections.

Other: Multiple daily insulin injections

Type 2 Bariatric surgery

Patients with type 2 diabetes who are enrolled in pre-operative weight loss protocol prior to bariatric surgery.

Procedure: Bariatric surgery

Type 2 conventional

Severely obese patients with type 2 diabetes who are to continue with non-surgical treatments of diabetes and obesity and with no planned bariatric surgery.

Other: Medical therapy for type 2 diabetes

Type 1 insulin pumpe follow-up

Patients with type 1 diabetes previously followed in an observational study with electrophysiological and psychophysical measures of retinal function.

Other: Insulin pump

Healthy

Healthy volunteers.

Interventions

Insulin pump therapy

Type 1 Insulin PumpType 1 insulin pumpe follow-up

Multiple daily insulin injections

Type 1 conventional therapy

Pre-operative weight loss and bariatric surgery.

Type 2 Bariatric surgery

Medical glucose-lowering therapy and non-surgical weight-lowering interventions.

Type 2 conventional

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

30 patients with type 1 diabetes and suboptimal metabolic regulation which is to be optimized by insulin pump therapy. 30 patients with type 1 diabetes and suboptimal metabolic regulation in whom insulin pump therapy is not planned. 20 patients with type 2 diabetes and suboptimal metabolic regulation who are enrolled in a pre-operative weight lowering protocol prior to bariatric surgery. 20 patients with type 2 diabetes and suboptimal metabolic regulation who are not enrolled in treatment protocols relating to bariatric surgery. 17 patients with type 1 diabetes on insulin pump therapy who were previously followed in an observational study of retinal function.

You may qualify if:

  • Patients with type 1 diabetes and suboptimal metabolic regulation.
  • Patients with type 2 diabetes and suboptimal metabolic regulation.

You may not qualify if:

  • Significant cataract
  • Glaucoma
  • Proliferative diabetic retinopathy fulfilling ETDRS treatment criteria.
  • Clinically significant macular edema fulfilling ETDRS treatment criteria.
  • Age-related macular degeneration
  • Prior surgery to the eye
  • Other serious eye disease
  • Hypertension

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Ophthalmology, Glostrup Hospital

Glostrup Municipality, 2600, Denmark

RECRUITING

MeSH Terms

Conditions

Diabetes MellitusDiabetic Retinopathy

Interventions

Insulin Infusion SystemsBariatric Surgery

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesRetinal DiseasesEye DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes Complications

Intervention Hierarchy (Ancestors)

Drug Delivery SystemsDrug TherapyTherapeuticsInfusion PumpsEquipment and SuppliesArtificial OrgansSurgical EquipmentBariatricsObesity ManagementSurgical Procedures, Operative

Study Officials

  • Oliver Klefter, MD

    Glostrup UH

    PRINCIPAL INVESTIGATOR
  • Michael Larsen, Professor, DMSci

    Glostrup UH

    STUDY DIRECTOR

Central Study Contacts

Oliver Klefter, MD

CONTACT

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 23, 2012

First Posted

January 25, 2012

Study Start

August 1, 2011

Primary Completion

December 1, 2016

Last Updated

March 11, 2015

Record last verified: 2015-03

Locations